The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | Advances in mesothelioma treatment
Dean Fennell, PhD, FRCP, of the University Hospitals Of Leicester NHS Trust, Leicester, UK, discusses advances in the treatment of mesothelioma, including the results of the MiST1 study (NCT03654833) which resulted in greater than 50% disease control in BAP1/BRCA1 deficient relapsed malignant mesothelioma treated with rucaparib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
